TrialArthritis research & therapy2024

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.

Narendra Maharaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.